AC Immune Seeks Partner For First Anti-Tau Vaccine To Reach The Clinic
This article was originally published in The Pink Sheet Daily
Executive Summary
The Swiss biotech raises $22 million in a Series D from its existing private investors to support its research into Alzheimer’s disease therapies.
You may also be interested in...
AC Immune Links with Piramal Imaging To Advance Alzheimer’s Research
Selecting the right patients for clinical trials of potential Alzheimer’s disease therapies could be easier if an agreement on the development of a PET-based diagnostic between the companies bears fruit.
Deal Watch: Shire Increases Rare Disease Holdings, Abbott Expands Latin American Interests
MedImmune and Bristol announce immuno-oncology combination trials with new partners on the same day, while AC Immune and Piramal Imaging will collaborate to develop an Alzheimer’s diagnostic to trace abnormal Tau protein in neuronal tissue.
AC Immune Links with Piramal Imaging To Advance Alzheimer’s Research
Selecting the right patients for clinical trials of potential Alzheimer’s disease therapies could be easier if an agreement on the development of a PET-based diagnostic between the companies bears fruit.